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Conclusion: 18F-FDG PET/CT is useful to target volumes 
delineation for radiotherapy planning, allowing a clear 
definition of GTV, not detected with 131I WBS. Disease 
response and local control justify future prospective studies. 
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Purpose or Objective: To evaluate long-term results, 
prognostic factors, quality of life (QoL) and voice and thyroid 
toxicity and risk of second tumors in T1N0M0 glottic 
carcinoma. 
 
Material and Methods: A total of 100 patients with stage 
T1N0M0 histologically proven squamous cell glottic carcinoma 
treated between 2000 and 2012 were retrospectively 
analyzed. Mean age: 62.14 years; 90 males, 10 female; stage: 
T1a:80, T1b:20. Treatment: radical external radiotherapy 
with a mean dose of 70 Gy (2Gy/fraction). Statistical 
analysis: Kaplan-Meier method and Chi-square test. In 35 
patients, we prospectively evaluated the Voice Handicap 
Index (VHI 30) and the QoL with (EORTC)–QLQ C30 
questionnaire and organ-specific EORTC-Head & Neck-35 
module. In the functional and QoL scales of the QLQ C30 
questionnaire a higher score represent better functioning and 
quality of life, whereas in symptoms scales of both 
questionnaires a high score implies a higher level of 
symptoms. The last two questions in QLQ C30 represents a 
QoL scale ranging from 1 (“very poor”) to 7 (“excellent”). 
Blood determination of TSH, T4, T3 levels was performed in 
19 patients. Second primary tumors were defined as those 
originated outside the head and neck area. 
 
Results: Median follow-up: 91.5 months. Five-and 10-year 
actuarial OS and disease free survival were 83% and 70%, and 
70% and 57% respectively. Five- and 10-year actuarial LC and 
metastasis free survival were 84% and 77%, and 97% and 94% 
respectively. Eighteen patients had recurrent disease. Mean 
time to local recurrence was 80 months. Sex, stage, grade 
and Overall Treatment Time were not statistically significant 
prognostic factors. Mean score (MS) for the VHI30 was 19.16, 
which is considered as a minimal amount of voice handicap. 
Patients reported excellent QoL in the C30 questionnaire 
which showed functional scores above 93 and symptoms 
scores below 14. The global health status and QoL scale were 
5.93 and 6, respectively, which should be considered as 
“good” or “very good”. In the H&N 35 questionnaire the 
worse scores were dry mouth and thick saliva (MS 30.6 for 
both). Most patients have no problems in open mouth, 
swallowing, speaking and social contact (MS of 0, 6.9, 18.6 
and 16.6, respectively). There were no patients with clinical 
or subclinical hypothyroidism. Mean TSH, T3, and T4 were 
2.32, 3.16 and 1.31, respectively. Mean TSH was not 
statistically different from normal values (P: 0.34) Eighteen 
patients (18%) had second tumors: 11 lungs, 2 prostates, 5 
others. Ten years probability of second lung cancer was 28%. 
 
Conclusion: In our series radical radiotherapy for T1 glottic 
cancer was well tolerated and achieved excellent tumor 
control comparable to surgery. In our opinion radical 
radiotherapy should be the standard treatment of these 
patients given the excellent results in QoL and voice 
preservation. The high probability of second lung cancer 
could justify performing thoracic CT scan during follow-up. 
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Purpose or Objective: We investigated the treatment 
outcome of induction bio-chemotherapy followed by IMRT for 
advanced nasopharyngeal carcinoma (NPC) and the 
prognostic impact of plasma EBV DNA viral load. 
 
Material and Methods: Forty-two NPC patients with 
previously untreated, stage III/IV received induction 
chemotherapy of weekly P-FL (cisplatin 60 mg/m2 d1, [5-
fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2] d8) ± 
docetaxel 50 mg/m2 or gemcitabine 1000 mg/m2 d15, for 10-
12 weeks and concurrent Cetuximab 400 mg/m2 day 1, then 
weekly 250 mg/m2. Conventional (70 Gy/35fr) or 
hyperfractionated (76.4 Gy/64fr for T4 tumor) RT were 
delivered by IMRT technique. Plasma EBV DNA levels were 
measured before, during and after treatment regularly. 
 
Results: Baseline characteristics are median age=44; 
male/female=28/14; performance status ECOG 0/1=13/12; 
stage III/IV=22/20, and pathological type (WHO) 
IIa/IIb=20/22. Each patient received a mean of 11 weekly 
cetuximab. During induction bio-chemotherapy period, 
cetuximb-associated toxicity included 100% skin rashes (grade 
50% III/IV), 64.3% (27/42) dry skin, 52.4% (22/42) paronychia, 
and 28.6% (12/42) hypomagnesia. Grade III/IV conventional 
toxicities were rare (11.9% leucopenia, 9.5% anemia, 2.4% 
thrombocytopenia, and 2.4% mucositis). Response after 
induction bio-chemotherapy revealed 50% CR and 50% PR. 
After a median follow-up of 24 months, there were 1 local, 1 
regional, and 5 distant failures. The 3-year local failure-free, 
neck failure-free, distant metastasis failure-free (DMFS), 
progression-free survival (PFS), and overall survivals (OS) 
were 96.6%, 96.0%, 87.4%, 79.9%, and 92.1% respectively. 
Patients with high pretreatment plasma EBV DNA predict 
significantly lower PFS and DMFS (P=0.0108 and P=0.004) but 
not OS (P=0.6291). Patients with detectable plasma EBV DNA 
after bio-chemotherapy had a significantly lower OS, PFS, 
and DMFS (P=0.0294, P=0.0078, and P=0.0082). Patients with 
persistently detectable plasma EBV DNA one week after IMRT 
predict a significantly lower PFS (P=0.0258). 
 
Conclusion: Induction Bio-chemotherapy followed by IMRT is 
a highly effective protocol with very low toxicity in advanced 
NPC. Plasma EBV DNA monitoring are the most important 
prognostic factors in outcome prediction. 
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Purpose or Objective: The choice of fractionation scheme in 
radiotherapy of head and neck cancer (HNC) is still debated. 
In fact it is well known that a shorter overall treatment time 
and a dose escalation, may improve loco-regional control of 
disease by reducing cell repopulation. Nevertheless, 
shortening overall treatment time can result in worse acute 
toxicity.Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB), allowing 
hypofractionation with a better sparing of the organs at risk, 
has showed promising results in terms of outcome and 
pattern of toxicity.In this study we retrospectively analyzed a 
series of patients with stage III-IV HNC treated with VMAT-SIB 
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radiotherapy, with the aim to verify possible correlations 
between the planned dose distributions to the main dose 
limiting structures and the observed levels of toxicity like 
mucositis, xerostomia and dysphagia. 
 
Material and Methods: Data of hystologically confirmed 
advanced HNC patients, in stage III and IV (AJCC), were 
reviewed in a retrospective dosimetric and clinical 
evaluation. Patients were treated with VMAT (RapidArc) and 
SIB in 33 fractions for a total dose of 69.96 Gy to the tumor 
and positive-nodes, and 54.45Gy to the elective volume, 
respectively. Toxicity was graded according to CTCAE3.0 
Correlation was explored between OAR dose parameters and 
related acute and late toxicities. 
 
Results: From December 2008 to August 2014, 102 patients 
were treated. Acute mucosal and swallowing toxicities higher 
than grade 3 were reported in only 11% and 6% of patients, 
respectively; late morbidities (G1-G2) were present in only 
3% of cases. No G3 Toxicity was reported. A statistically 
significant correlation was found between the dosimetric 
parameters of oral cavity V30Gy, V40Gy, and V70Gy, and 
mucosal toxicity (p = 0.01, 0.03, and 0.05, respectively). 
Concerning salivary glands, late toxicity profile was worse 
compared to acute side effects, with 19% of persisting late 
grade equal or higher than 2. Regarding the constrictors and 
the swallowing toxicity, most of the dosimetric parameters of 
the inferior constrictor muscle (mean dose, D1/2V, D1/3V, 
D2/3V) were significant at the univariate analysis, while no 
correlations were found for middle and superior constrictors. 
With a median follow-up of 19 months (range 1-61 months), 
Overall Survival (OS) at 3 and 5 years was 83%±4% and 
73%±10%. Mean OS was 51±3 months. Disease Free Survival 
(DFS) at 3 and 5 years was 71%±7%, and 34%±16%. Mean DFS 
was 43±3 months. 
 
Conclusion: Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB), that allow a shorter 
overall treatment time, a dose escalation, associated with a 
better sparing of OARs, showed a good toxicity profile. From 
our analysis toxicity to dose-limiting structures was 
significantly correlated to the dosimetric parameters 
explored. 
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Purpose or Objective: To investigate the association 
between temporally robust domains of patient-reported 
trismus symptoms with mouth-opening ability as assessed by 
maximal interincisal opening distance (MIO) in head and neck 
cancer (HNC) patients treated with radiotherapy (RT). 
 
Material and Methods: The study included 196 patients 
previously treated with primary state-of-the-art RT for HNC 
in 2007-2012. A five answering-category-based 
(no/mild/moderate/severe/very severe symptom) patient-
reported trismus questionnaire (Gothenburg Trismus 
Questionnaire, GTQ) was completed pre-RT, and at 3, 6, and 
12 months post-RT. This study focuses on the 14/21 
potentially RT-induced physical trismus symptoms from GTQ. 
At each follow-up, symptom domains were generated by 
means of factor analysis and these symptoms were correlated 
with MIO (categorized into five intervals (mm): 1: >50; 2: 
>40-≤50; 3: >35-≤40; 4: >25-≤35; 5: ≤25) for each follow-up 
using Pearson’s correlation coefficient (Pr). 
 
Results: The three symptom domains Jaw aches/pains, Jaw-
related problems, and Eating limitations were identified at 
each follow-up, and included one, two and three temporally 
robust symptoms, respectively. Correlations between MIO and 
these symptoms were weak to modest (Pr= 0.22-0.58; Table) 
with the overall stronger correlations for ‘Opening mouth 
difficulty’ and ‘Current mouth-opening ability’ in the Jaw-
related problems domain at 6 and at 12 months post-RT 
(Pr=0.49-0.58; Figure). 
 
 
 
 
 
Conclusion: Mouth-opening distances can be explained in 
terms of associated patient-reported symptom severities on 
jaw-related problems. Translating the patient’s experience 
into objective measurements and vice versa widens 
possibilities to monitor and possibly prevent progression of 
trismus symptoms after RT. 
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Purpose or Objective: Determination of expression of EGFR 
in premalignant and malignant lesions of the oral cavity and 
evaluating the role of Gefitinib in the same 
 
Material and Methods: 130 Patients with premalignant and 
malignant lesions of oral cavity from JK cancer institute, 
Kanpur were selected. EGFR status evaluation was done in all 
the patients. Premalignant lesions over expressing EGFR were 
observed for transformation into malignant lesions and were 
given Tab Gefitinib 250 mg OD daily. Malignant lesions with 
over expression of EGFR were randomly divided into 2 groups 
first group consisted of patients who were given 
CCRT(cisplatin). The other group had the same regimen but 
with the addition of Tab Gefitinib 250 mg daily 
 
Results: Out of 130 patients registered 53 were premalignant 
out of which EGFR(+) positive in 73%( 39) patients. EGFR( 
++)over expression were in 8%(4)patients, EGFR negative in 
18%(10) patients. 77 were malignant lesions EGFR positive in 
89%(51) patients. EGFR(+)in 38%(27) of patients, EGFR(++)in 
40%( 28) patients ,EGFR(+++) were expressed by 11%( 11) 
patients. EGFR negative in 11%(11 patients) 
